The Home Depot Announces the Nomination of Asha Sharma for Election to its Board of Directors at 2025 Annual Meeting
ATLANTA, April 7, 2025 /PRNewswire/ -- The Home Depot®, the world's largest home improvement retailer, today announced that Asha Sharma, Microsoft corporate vice president and head of product, AI platform, has been nominated for election to its Board of Directors at its 2025 annual meeting of shareholders, which will be held virtually on May 22, 2025.
Sharma leads product development and computational design for the artificial intelligence platform which includes models, tools and services for Microsoft's enterprise, developer and data science customers. Prior to joining Microsoft, she held various leadership roles at Instacart, Facebook (now known as Meta), and home service software provider Porch Group, bringing a blend of leadership experience in technology, data protection and cybersecurity, e-commerce, supply chain, finance, operations and marketing.
'We are continuing to enhance our capabilities to provide our customers with an interconnected, frictionless shopping experience that enables them to seamlessly blend the digital and physical worlds,' said Ted Decker, chair, president and CEO of The Home Depot. 'As we continue to evolve the interconnected experience for our associates and customers, including through the use of generative AI tools, Asha's extensive technology and operational experience will be a tremendous asset.'
ABOUT THE HOME DEPOT
The Home Depot is the world's largest home improvement specialty retailer. At the end of the fourth quarter, the company operated a total of 2,347 retail stores and over 780 branches across all 50 states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, Guam, 10 Canadian provinces and Mexico. The Company employs over 470,000 associates. The Home Depot's stock is traded on the New York Stock Exchange (NYSE: HD) and is included in the Dow Jones industrial average and Standard & Poor's 500 index.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Verge
2 hours ago
- The Verge
'You can now easily pause, play, skip forward or backward, and seek via the progress bar right from the picture-in-picture window,'
Microsoft Edge's picture-in-picture mode is getting better controls. according to a blog post. I don't use Edge, but these seem like good upgrades.
Yahoo
2 hours ago
- Yahoo
Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction
Parents pursuing IVF now have a new level of choice to empower their family planning NEW YORK, June 4, 2025 /PRNewswire/ -- With U.S. birthrates plummeting and IVF on the rise, Nucleus Genomics today launched Nucleus Embryo, the first genetic optimization software that lets parents see and understand a complete genetic profile to select an embryo. "Before there's a heartbeat, there's DNA," said Kian Sadeghi, founder and CEO of Nucleus. "One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage. Most clinics stop at whether an embryo will develop. For many parents, that's not enough. Patients have long asked for more transparency from clinics, and Nucleus Embryo is an important step toward complete data ownership for parents planning their families." The software enables parents to analyze and compare up to 20 embryos across over 900 hereditary conditions and 40 additional analyses beyond basic viability, spanning cancers, chronic conditions, appearance, cognitive ability, mental health, and more. To widen access to the software, Nucleus will partner with Genomic Prediction, the first company to offer genome-wide screening on embryos. The partnership sets a new standard in genetic medicine, continuing Genomic Prediction's decade-long history of giving hopeful parents the best possible chance of implanting healthy embryos. The company's analyses focus on hereditary conditions, acting as the first line of defense against chronic and rare diseases. "As an organization, we are committed to supporting patients' rights to their DNA and any information that can aid in their family-building journey," said Kelly Ketterson, CEO of Genomic Prediction. "We have a legacy of innovation aimed at providing patients with access to the best scientific resources. Our partnership with Nucleus opens access to information our patients have requested and allows us to uphold our commitment to this legacy." Nucleus' partnership with Genomic Prediction reflects a growing shift in how parents think about genetics as a tool to give children the best possible start in life. A wide-ranging study of Americans found the majority accepted the use of genetic technology to choose embryos based on health and personality traits. Four in 10 parents would use genetic optimization as another tool to understand their future child's cognitive abilities. Most women undergo three to six IVF cycles before successfully having a baby, with each cycle costing up to $25,000. Many embryos are unviable within days of being fertilized, leaving parents with few to choose from. Facing high stakes, clinicians often recommend genetic testing to optimize a couple's chances of a healthy pregnancy. But these tests typically stop at a select number of hereditary conditions and chromosome count. Now, advanced genetic analysis from Nucleus gives parents a new window into the health and well-being of their future child. Nucleus Embryo provides a comprehensive genetic profile for each embryo, encompassing hereditary genetic diseases, like cystic fibrosis and hemochromatosis, alongside genetic measures of cognitive ability, mental health, and risk for chronic diseases. Wide access to genetic insights for embryos can also help extend lifespan from the earliest stages of life. While more than half of all deaths annually in the U.S. are attributed to chronic, age-related conditions — such as Alzheimer's disease, diabetes, cancer, and heart disease — research shows embryonic selection can materially help reduce disease risk for these conditions. "We celebrate health optimization and the pursuit of longevity in every other part of life via our focus on training, supplements, and sleep," Sadeghi said. "We all know health isn't just the absence of disease. It's the ability to understand our bodies and genetic makeup to reach our full potential. Now we can apply this principle to life's inception." About Nucleus Genomics Nucleus builds software for generational health. Inspired by the loss of his cousin who died of a rare — yet preventable — genetic disease, Nucleus founder and Thiel Fellow Kian Sadeghi left an Ivy League university to build a product that could have saved her life. Our advanced DNA health test and analysis takes the guesswork out of your health, whether it's perfecting your protocols, knowing your risk for cancer, or planning for a healthy family. Follow us on social media @nucleusgenomics. About Genomic Prediction Genomic Prediction, Inc. is the frontrunner in advanced embryo screening. Our proprietary LifeView platform is state-of-the-art technology that assesses embryos for genetic health aimed at improved IVF outcomes. The LifeView Embryo Health Score Test (EHS) offers insight into the likelihood of developing conditions driven by multiple genes. It tests for significant health issues, including cardiovascular disease, diabetes mellitus, certain cancers, and mental health conditions. The EHS results are derived from the same embryo sample used in the following PGT tests: PGT-A: Identifies chromosome abnormalities in embryos. PGT-A+: Pinpoints the origin (paternal, maternal, or embryonic) of chromosome abnormalities. PGT-M: Decreases the chances of passing on monogenic (single-gene) conditions. PGT-SR: Detects chromosome abnormalities and structural imbalances, providing clarity between normal and balanced chromosomes. View original content to download multimedia: SOURCE Nucleus
Hamilton Spectator
3 hours ago
- Hamilton Spectator
Alberta resumes buying U.S. alcohol, months after pause meant to fight tariffs
EDMONTON - Alberta is buying American alcohol and gambling machines again, three months after Premier Danielle Smith announced restrictions aimed at fighting back against U.S. tariffs. Service Alberta Minister Dale Nally said Friday that the move signals a 'renewed commitment to open and fair trade' with the United States. Smith said in March that the province would no longer buy U.S. alcohol and video lottery terminals, or sign contracts with American companies. Alberta's liquor stores are privately owned but must order stock through the provincial government. That came a day after U.S. President Donald Trump slapped heavy tariffs on Canadian goods and energy. Other premiers also announced bans on U.S. liquor along with other proposed penalties. Nally said in a statement that the decision to resume buying U.S. alcohol and gambling machines 'sets the stage for more constructive negotiations' ahead of a renewal of the Canada-U.S.-Mexico trade agreement. The agreement, known as CUSMA, was negotiated during the first Trump administration and is up for a mandatory review in 2026. 'Prime Minister Mark Carney has made a clear effort to reset the relationship with the U.S. administration, and Alberta's government supports this approach,' Nally said. 'We are focused on highlighting Alberta's role as a responsible and collaborative trading partner and will continue working alongside other provinces to advocate for a tariff-free relationship.' The minister said Albertans are encouraged to continue supporting local producers, even as more U.S. options return to store shelves. In April, the province paused its policy around procurement from U.S. companies in what Nally called 'the spirit of diplomacy.' This report by The Canadian Press was first published June 6, 2025. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
